<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - TERBINAFINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>TERBINAFINE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#exceptionsToLegalCategory" data-toggle="tab">Exceptions to legal category</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Tinea pedis</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using tablets</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply 1&#8211;2 times a day for up to 1 week, to be applied thinly.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                250 mg daily for 2-6 weeks.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Tinea corporis</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using tablets</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply 1&#8211;2 times a day for up to 1&#8211;2 weeks, to be applied thinly, review treatment after 2 weeks.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                250 mg once daily for 4 weeks.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Tinea cruris</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using tablets</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply 1&#8211;2 times a day for up to 1&#8211;2 weeks, to be applied thinly, review treatment after 2 weeks.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                250 mg once daily for 2-4 weeks.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Dermatophyte infections of the nails</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using tablets</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                250 mg once daily for 6 weeks-3 months (occasionally longer in toenail infections).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Cutaneous candidiasis</span>,
                <span class="indication">Pityriasis versicolor</span>,
            </h4>
            <p class="specificity"><span class="route">To the skin using cream</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply 1&#8211;2 times a day for 2 weeks, to be applied thinly, review treatment after 2 weeks.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use</h3>
              <p>Manufacturer advises use only if potential benefit outweighs risk&#8212;<i>animal</i> studies suggest no adverse effects.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Manufacturer advises use only if potential benefit outweighs risk&#8212;no information available.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Manufacturer advises avoid&#8212;elimination reduced.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Use half normal dose if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup> and no suitable alternative available.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> abdominal discomfort, anorexia, arthralgia, diarrhoea, dyspepsia, headache, myalgia, nausea, rash, urticaria,
              </p>
              <p>
                <strong>uncommon:</strong> taste disturbance,
              </p>
              <p>
                <strong>rare:</strong> cholestasis, dizziness, hepatitis, hypoaesthesia, jaundice, liver toxicity, malaise, paraesthesia,
              </p>
              <p>
                <strong>veryRare:</strong> alopecia, blood disorders, lupus erythematosus-like effect, neutropenia, photosensitivity, serious skin reactions, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis,
              </p>
              <p>
                <strong>notKnown:</strong> disturbances in smell, exacerbation of psoriasis, hearing disturbances, influenza-like symptoms, pancreatitis, rhabdomyolysis, vasculitis, erythema, hypersensitivity reactions, itching, mild burning sensation, occasional local irritation,
              </p>
        
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
                <p class="title">Liver toxicity</p>
              <p>Discontinue treatment if liver toxicity develops (including jaundice, cholestasis and hepatitis).</p>
            </section>
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
                <p class="title">Serious skin reactions</p>
              <p>Discontinue treatment in progressive skin rash (including Stevens-Johnson syndome and toxic epidermal necrolysis).</p>
            </section>
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use</h3>
                <p class="title">Topical application</p>
              <p>Treatment should be discontinued if side effects are severe.</p>
            </section>
        
      </section>





      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>With oral use:</strong>
            autoimmune disease (risk of lupus-erythematosus-like effect)
          </li>
          <li>
              <strong>With oral use:</strong>
            psoriasis (risk of exacerbation)
          </li>
          <li>
              <strong>With topical use:</strong>
            contact with eyes and mucous membranes should be avoided
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Monitor hepatic function before treatment and then every 4&#8211;6 weeks during treatment&#8212;discontinue if abnormalities in liver function tests.</p>
            </section>
      </section>









      <section class="tab-pane" id="exceptionsToLegalCategory">
        <h2>Exceptions to legal category</h2>

            <section class="exceptionsToLegalCategory">
              <p>Preparations of terbinafine hydrochloride (maximum 1%) can be sold to the public for use in those over 16&#8239;years for external use for the treatment of tinea pedis as a cream in a pack containing maximum 15&#8239;g, or for the treatment of tinea pedis and cruris as a cream in a pack containing maximum 15&#8239;g, or for the treatment of tinea pedis, cruris, and corporis as a spray in a pack containing maximum 30&#8239;mL spray or as a gel in a pack containing maximum 30&#8239;g gel.</p>
            </section>
      </section>


      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of TERBINAFINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            oral solution,

            <div id="PHP77168"><a href="../medicinalForm/PHP77168.html" data-target="#PHP77168" data-action="load">Tablet</a></div>
            <div id="PHP77194"><a href="../medicinalForm/PHP77194.html" data-target="#PHP77194" data-action="load">Liquid</a></div>
            <div id="PHP77175"><a href="../medicinalForm/PHP77175.html" data-target="#PHP77175" data-action="load">Cream</a></div>
            <div id="PHP77189"><a href="../medicinalForm/PHP77189.html" data-target="#PHP77189" data-action="load">Gel</a></div>
            <div id="PHP77182"><a href="../medicinalForm/PHP77182.html" data-target="#PHP77182" data-action="load">Spray</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
